Compare HOFT & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | ORMP |
|---|---|---|
| Founded | 1924 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.4M | 170.3M |
| IPO Year | 1999 | 2010 |
| Metric | HOFT | ORMP |
|---|---|---|
| Price | $15.43 | $4.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 55.3K | ★ 167.1K |
| Earning Date | 04-16-2026 | 05-14-2026 |
| Dividend Yield | 3.79% | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | 0.10 | ★ 0.91 |
| Revenue | ★ $278,139,000.00 | $2,000,000.00 |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | $151.60 | ★ $4.73 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $8.62 | $1.98 |
| 52 Week High | $18.09 | $5.19 |
| Indicator | HOFT | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 54.10 |
| Support Level | $15.08 | $3.90 |
| Resistance Level | $15.97 | $5.10 |
| Average True Range (ATR) | 0.77 | 0.19 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 81.50 | 61.94 |
Hooker Furnishings Corp is a designer, marketer, and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality, and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segments: Hooker Branded segment, Domestic Upholstery segment, and All Other. It generates the majority of its revenue from the Hooker Branded segment.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.